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ARTICLE
Dengue virus-reactive CD8+ T cells mediate
cross-protection against subsequent Zika virus
challenge
Jinsheng Wen1,2, Annie Elong Ngono1, Jose Angel Regla-Nava1, Kenneth Kim1, Matthew J. Gorman3,
Michael S. Diamond3 & Sujan Shresta1,2,4
Zika virus (ZIKV) and dengue virus (DENV) are antigenically related ﬂaviviruses that share
cross-reactivity in antibody and T cell responses, and co-circulate in increasing numbers
of countries. Whether pre-existing DENV immunity can cross-protect or enhance
ZIKV infection during sequential infection of the same host is unknown. Here, we show that
DENV-immune Ifnar1−/− or wild-type C57BL/6 mice infected with ZIKV have cross-reactive
immunity to subsequent ZIKV infection and pathogenesis. Adoptive transfer and cell
depletion studies demonstrate that DENV-immune CD8+ T cells predominantly
mediate cross-protective responses to ZIKV. In contrast, passive transfer studies suggest
that DENV-immune serum does not protect against ZIKV infection. Thus, CD8+ T cell
immunity generated during primary DENV infection can confer protection against secondary
ZIKV infection in mice. Further optimization of current DENV vaccines for T cell responses
might confer cross-protection and prevent antibody-mediated enhancement of ZIKV
infection.
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The closely related ﬂaviviruses dengue virus serotypes 1–4(DENV1–4) and Zika virus (ZIKV) share the Aedes aegyptivector and co-circulate in overlapping geographic
ranges1–3. Cases of ZIKV infection in DENV-immune indivi-
duals, DENV infection of ZIKV-immune individuals, and even
concurrent infection with both viruses are inevitable4. DENV and
ZIKV share 52–57% total amino acid homology5,6, and their
immunologic cross-reactivity has been described previously7–11.
Passive transfer experiments using plasma from DENV immune
hosts have indicated that DENV antibodies (Abs) can enhance
ZIKV pathogenesis12. However, little is known about
DENV–ZIKV heterologous immune responses in the context of a
sequentially infected host, and whether these responses may
provide protection against or contribute to pathogenesis.
ZIKV infection during pregnancy has been shown to result in
congenital malformations including microcephaly13, whereas
in adults infection is associated with encephalitis14, genital
tract infection and sexual transmission14,15, Guillain Barré
Syndrome16, and immune-mediated thrombocytopenia17. DENV
infection is associated with a range of clinical severity from
asymptomatic illness to life-threatening dengue hemorrhagic
fever/dengue shock syndrome18. Epidemiologic studies indicated
that this severe form of DENV infection is most commonly
associated with secondary heterotypic infection19,20, in which an
individual is infected by a second heterotypic DENV serotype
following seroconversion to at least one other serotype.
Mechanistically, the non-mutually exclusive hypotheses of
antibody-dependent enhancement (ADE) and T cell original
antigenic sin21 have been proposed to explain why infection with
a ﬁrst virus can increase disease severity upon future infection
with a second antigenically related virus.
Thorough epidemiological studies that characterize human
DENV/ZIKV cross-reactive immune responses will take years to
complete. However, laboratory evidence suggests that DENV and
ZIKV cross-reactive Abs can reciprocally promote ADE of
ZIKV9,10,12,22 and DENV8,23. Consequently, vaccines for DENV,
ZIKV, and other cross-reactive ﬂaviviruses could sensitize indi-
viduals to more severe infection with a heterologous
ﬂavivirus24–26. Although vaccinology continues to focus on
optimizing durable humoral immunity, evidence of ADE and T
cell original antigenic sin in the contexts of sequential ﬂavivirus
infection or ﬂavivirus immunogen exposure mandates a com-
prehensive interrogation of heterologous immunity and the cru-
cial mechanisms responsible for protective vs. harmful immune
responses.
Although initial studies supported a role for pathogenic,
serotype cross-reactive T cells in promoting original antigenic sin
in DENV infection27–31, more recent data indicate a protective
role for T cells is HLA-linked. CD8+ T cells are activated in
DENV-infected patients32,33, and DENV-immune individuals
have both serotype-speciﬁc as well as cross-reactive CD8+ T cells
that produce IFNγ and TNF, and exhibit cytotoxic
functionality27–29,34,35. Additionally, recent studies have revealed
that the magnitude and breadth of DENV-speciﬁc CD8+ T cell
responses are associated with HLA alleles that correlate with
clinical dengue disease36,37.
Findings in mouse models have suggested a protective role for
CD8+ T cells in DENV and ZIKV infection. A recent study in
type I interferon (IFN) receptor (IFNAR)-deﬁcient HLA-B*0702
and HLA-A*0101 transgenic mice demonstrated that CD8+
T cells primed with cross-reactive DENV peptide epitopes could
have protective activity against ZIKV38. Another study in LysM-
Cre+Ifnar1ﬂ/ﬂ C57BL/6 mice, which lack IFNAR in a subset of
myeloid cells and posseses IFNAR-competent T cells, showed that
depletion of CD8+ T cells results in increased ZIKV replication,
ZIKV-speciﬁc CD8+ T cells have cytotoxic activity in vivo, and
adoptive transfer of ZIKV-primed CD8+ T cells reduces ZIKV
replication39. Prior studies using models of DENV infection in
C57BL/6 and 129/Sv mice globally lacking IFNAR or both type I
and II IFN receptors have used similar loss-of-function (CD8+ T
cell depletion) and gain-of-function (CD8+ T cell transfer and
peptide immunization) approaches to demonstrate a critical role
for CD8+ T cells in protection against DENV infection and
disease40–42. Additionally in the context of secondary DENV
infections, studies in these IFNAR-deﬁcient mice have revealed
that CD8+ T cells are required for protection against heterotypic,
but not homotypic, secondary DENV infection43 and that CD8+
T cells can confer protection against DENV infection even under
ADE conditions44. Collectively, these results support roles for
CD8+ T cells in cross-protection against DENV and ZIKV
infection. Notwithstanding these studies, the following key
questions have not been answered: Does previous DENV expo-
sure confer cross-protection against ZIKV, as observed in the
context of heterotypic reinfection with different DENV serotypes?
What are the roles of cellular vs. humoral immunity in mediating
such cross-protection against ZIKV?
Here, we explored the clinical and virological outcomes, and
explored the immunological mechanisms in DENV-immune
mice subsequently challenged with ZIKV. We show that DENV
immunity can confer protection against ZIKV infection in the
same host. By depleting naive CD8+ T cells and transferring
DENV-immune serum or CD8+ T cells, we demonstrated that
CD8+ T cells, and not DENV-reactive Abs in serum, mediate
cross-protection against ZIKV infection. These ﬁndings have
implications for DENV and ZIKV vaccine development efforts.
Results
Cross-reactivity of ZIKV CD8+ T cell epitopes to DENV2. We
recently identiﬁed ZIKV-derived peptide epitopes recognized by
CD8+ T cells in H-2b mice39. We used this information to
identify ZIKV epitopes that were cross-reactive with DENV in
congenic H-2b Ifnar1−/− mice. Ifnar1−/− mice were used because
ZIKV does not efﬁciently inhibit type I IFN receptor signaling or
replicate enough to cause disease pathogenesis in adult wild-type
(WT) H-2b mice45. Ifnar1−/− mice were infected with
DENV2 strain S221, followed by detection of peptide-speciﬁc
IFNγ-secreting CD3+ CD8+ T cells in the spleen via intracellular
cytokine staining (ICS) assay on day 7 after infection. The
percentages of CD3+CD8+IFNγ+ T cells in the spleen from
DENV-infected mice after stimulation with ZIKV peptides
from prM44–52, E4–12, E7–15, NS3347–355, and NS518–27 were
0.67± 0.15%, 0.55± 0.1%, 0.59± 0.14%, 0.58± 0.14%, and
0.59± 0.12%, respectively (mean± SEM, two independent
experiments, Supplementary Fig. 1a). CD3+CD8+ T cells directed
to ZIKV epitopes prM44–52, E7–15, NS3347–355, and NS518–27 also
co-expressed IFNγ and TNF (Supplementary Fig. 1b) and IFNγ
and CD107a (Supplementary Fig. 1c), exhibiting a polyfunctional
phenotype. Altogether, these results identify a total of six
H-2b-restricted, CD8+ T cell epitopes in ZIKV that are cross-
reactive with DENV.
Cross-reactivity of DENV2 CD8+ T cell epitopes to ZIKV. The
percent identity between the six ZIKV-derived epitopes that are
cross-reactive with DENV2 and corresponding DENV2 peptides
ranged from 44 to 89% (Table 1). To assess the reciprocal cross-
reactivity of DENV2 epitopes to ZIKV, Ifnar1−/− mice were
inoculated with ZIKV strain FSS13025 and splenocytes were
harvested on day 7 post infection to measure antigen-speciﬁc T
cell responses via ICS assay upon stimulation with ﬁve different
DENV2 peptide variants (DENV2-prM44–52, DENV2-E4–12,
DENV2-E7–15, DENV2-NS3347–355, and DENV2-NS518–27)
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(Table 1). The frequencies of CD3+CD8+IFNγ+ T cells after ZIKV
infection that were restimulated ex vivo with DENV2-E4–12,
DENV2-E7–15, and DENV2-NS3347–355 were 2.92± 0.18%, 0.56±
0.1%, and 0.55± 0.11%, respectively (two independent experi-
ments, Supplementary Fig. 2a). CD3+CD8+ T cells stimulated
with the DENV2-E4–12 peptide also co-expressed IFNγ and TNF
(Supplementary Fig. 2b) and IFNγ and CD107a (Supplementary
Fig. 2c). Thus, of ﬁve H-2b-restricted, DENV2-derived CD8+ T
cell epitopes tested, four exhibited cross-reactivity with ZIKV.
CD8+ T cell-dependent DENV2 immunity reduces ZIKV bur-
den. To explore the role of DENV immunity in protection vs.
pathogenesis during ZIKV infection, we challenged DENV2-
immune Ifnar1−/− mice (28 days post infection) with ZIKV strain
FSS13025 and determined antigen-speciﬁc CD8+ T cell responses
and viral titers in sera and tissues at day 3 after ZIKV challenge.
Day 3 post ZIKV challenge was chosen for analysis of the T cell
and viral phenotype to focus our study on the adaptive memory
but not primary T cell response; this decision was based on prior
studies demonstrating that the CD8+ T cell response to primary
DENV or ZIKV infection in mice is not observed on day 3 but
becomes detectable after day 5 of infection39–41. Accordingly, a
cross-reactive peptide-speciﬁc CD8+ T cell immune response was
absent in naive (Fig. 1a, c) but present in DENV2-immune mice
(Fig. 1b). Infectious ZIKV levels in the serum, liver, brain,
eye, and testis of DENV2-immune mice were 25-fold, 91-fold,
273-fold, 25-fold, and 383-fold lower, respectively, than in naive
mice (isotype DENV2-immune vs. isotype Naive in Fig. 1e–i).
When a depleting anti-mouse CD8 monoclonal Ab was admi-
nistered, the majority of cross-reactive peptide-speciﬁc CD8+
T cells were absent (Fig. 1d), and infectious ZIKV levels in the
serum, liver, brain, eye, and testis of CD8+ T cell-depleted
DENV2-immune mice were 159-fold, 174-fold, 424-fold, 17-fold,
and 217-fold higher than isotype control Ab-treated, CD8+ T cell-
sufﬁcient DENV2-immune mice (anti-CD8 DENV2-immune vs.
isotype DENV2-immune in Fig. 1e–i). Notably, infectious ZIKV
in the serum from CD8+ T cell-depleted DENV2-immune mice
was not the same as in naive mice (anti-CD8 DENV2-immune vs.
isotype Naive and anti-CD8 Naive in Fig. 1e); rather, ZIKV levels
in sera of CD8+ T cell-depleted DENV2-immune mice was higher
(5–6-fold, two-tailed Mann–Whitney test, P< 0.01) than in both
groups of naive mice. Taken together, these results demonstrate
that prior DENV immunity confers cross-protection against
ZIKV infection through a CD8+ T cell-dependent mechanism.
Based on a published study demonstrating that CD8+ T cells can
prevent DENV ADE44, the higher level of ZIKV in the serum of
CD8+ T cell-depleted DENV2-immune mice relative to naive
mice suggests that CD8+ T cells also might control the ADE
induced by cross-reactive DENV Abs following ZIKV infection.
DENV2 immune sera-mediated neutralization of ZIKV
in vitro. To evaluate the role of the DENV-immune Ab response
in mediating protection or enhancement during ZIKV infection,
we collected sera from naive and DENV2-infected Ifnar1−/− mice
on day 28 after infection. We ﬁrst tested the DENV2-immune
sera for their ability to bind DENV2 and ZIKV by ELISA.
DENV2-immune sera bound to both DENV2 and ZIKV, with
lower endpoint titers (EPTs) against ZIKV than DENV2 (Sup-
plementary Fig. 3). We next assessed whether the DENV2-
immune sera could neutralize DENV2 and ZIKV in vitro using a
ﬂow cytometry-based neutralization assay46. As expected, naive
mouse serum failed to neutralize DENV2 or ZIKV (Fig. 2a). In
comparison, DENV2-immune serum efﬁciently neutralized
DENV2, with 50% neutralization titer (NT50) of ~1:180. DENV2-
immune serum could also neutralize ZIKV weakly, with an NT50
of ~1:15. These results demonstrate that DENV2-immune sera
can bind and neutralize both DENV2 and ZIKV in vitro,
although levels are lower against ZIKV relative to DENV2.
DENV2-immune sera do not limit ZIKV infection in vivo. We
next examined the capacity of DENV2-immune sera to neutralize
ZIKV in Ifnar1−/− and WT mice. High volumes (300 or 600 μl) of
naive mouse serum, and low (33 μl), medium (100 μl), and high
volumes (300 or 600 μl) of DENV2-immune serum were trans-
ferred passively via retro-orbital route to naive Ifnar1−/− mice.
One day after the serum transfer, mice were challenged with
ZIKV, followed by analysis of the splenic CD8+ T cell response
and ZIKV replication in various tissues on day 3 after the viral
challenge. As expected, at this early time point after ZIKV chal-
lenge in naive settings, no signiﬁcant peptide-speciﬁc CD8+ T cell
responses were detected in all mouse groups (Supplementary
Fig. 4). Passive transfer of DENV2-immune serum from Ifnar1−/−
donor mice did not reduce infectious ZIKV levels in any tissues of
Ifnar1−/− recipient mice, and if anything, slight enhancement was
observed in the serum of mice transferred with 300 μl of immune
serum (Fig. 2b). When we increased the serum volume to 600 μl,
we observed neither neutralization nor enhancement (Fig. 2c). In
parallel experiments, high volumes (75 μl) of naive WT mouse
serum, and high (75 μl), medium (25 μl), and low volumes (8.3 μl)
of DENV2-immune serum obtained from WT mice were trans-
ferred passively via retro-orbital route to 2-week-old WT mice
(Supplementary Fig. 5a, b). In a separate study with 4-week-old
WT recipients, 200 μl of naive or DENV2-immune serum
obtained from WT mice was retro-orbitally transferred (Supple-
mentary Fig. 5c, d). Similar to results obtained from experiments
with DENV2-immune serum obtained from Ifnar1−/− mice,
DENV2-immune serum harvested from WT mice did not
decrease ZIKV levels in tissues. These results suggest that DENV-
immune Abs play a minimal role in cross-protection against
subsequent ZIKV infection.
DENV2-reactive CD8+ T cells protect against ZIKV challenge.
Given the absence of protection after serum transfer, we assessed
whether DENV-exposed CD8+ T cells were sufﬁcient to control
ZIKV infection. Ifnar1−/− mice were inoculated with DENV2 for
28 days, followed by isolation of DENV2-exposed CD8+ memory
T cells from the spleen. 1 × 107 DENV2-exposed splenic CD8+
T cells then were transferred adoptively to naive Ifnar1−/− reci-
pient mice. High numbers of cross-reactive peptide-speciﬁc CD8+
T cells were detected in mice receiving 1 × 107 DENV2-exposed
CD8+ T cells, as compared to mice receiving 1 × 107 naive CD8+
Table 1 ZIKV epitopes and DENV2 variants
Peptidesa Sequencesb Conservationc
MR-prM20–28 ISFATTLGV 44%
DENV2-prM20–28 LLFKTEDGV
FSS/MR-prM44–52 ATMSYECPM 44%
DENV2-prM44–52 DT I TYKCP L
FSS/MR-E4–12 IGVSNRDFV 89%
DENV2-E4–12 IG I SNRDFV
FSS/MR-E7–15 SNRDFVEGM 89%
DENV2-E7–15 SNRDFVEGV
FSS/MR-NS3347–355 PSVRNGNEI 56%
DENV2-NS3347–355 PS I KAGNDI
FSS/MR-NS518–27 CAEAPNMKI I 50%
DENV2-NS518–27 E SEVPN L DI I
aZIKV peptides in bold are positive as determined via ICS assays in DENV2-infected mice
bAmino acid residues underlined are conserved between the ZIKV epitope and DENV2 variant
c% shared amino acids between ZIKV and DENV2
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T cells (Fig. 3a). In serum and all organs, transfer of 1 × 107
DENV2-exposed CD8+ T cells led to signiﬁcant reduction in
infectious ZIKV levels (Fig. 3b). Consistent with these results with
Ifnar1−/− mice, adoptive transfer of DENV-exposed CD8+ T cells
isolated from WT mice also resulted in a signiﬁcant decrease in
ZIKV levels in the serum and liver of WT recipients (Fig. 4a, b).
Thus, DENV-reactive CD8+ T cells can mediate cross-protection
against ZIKV infection by reducing virus levels in multiple
tissues.
We next evaluated whether DENV-exposed CD8+ T cells were
sufﬁcient to protect against lethal ZIKV disease in naive Ifnar1−/−
mice, which support high levels of ZIKV replication and succumb
even at a low viral challenge dose45. Naive Ifnar1−/−mice received
either 1 × 107 naive CD8+ T cells or 1 × 107 DENV2-exposed
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Fig. 1 ZIKV tissue burden in DENV-immune Ifnar1−/−mice in the presence or absence of CD8+ T cells. Ifnar1−/− mice were immunized intraperitoneally with
DENV2 (2 × 102 FFU) for 28 days. Naive and DENV2-immune mice were injected intraperitoneally with isotype control Ab and anti-mouse CD8 Ab at
3 days and 1 day before ZIKV challenge. Three days post ZIKV challenge, peptide-speciﬁc CD3+CD8+IFNγ+ T cells (a–d; a, c naive mice; b, d DENV2-
immune mice) and infectious ZIKV levels in sera (e) and indicated organs (f–i) were detected using ICS assay and FFA, respectively. Data were
pooled from two independent experiments with n= 3–5 mice per group per experiment and expressed as mean± SEM. *p< 0.05, **p< 0.01, ***p< 0.001,
****p< 0.0001. A Kruskal–Wallis one-way ANOVA was used for a–d while two-tailed Mann–Whitney test was used for e–i. Supplementary Tables 1 and 2
provide exact values of n and p
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CD8+ T cells from the spleen, followed by challenge of the
recipient mice with 1 × 103 focus-forming unit (FFU) of ZIKV.
Mice were observed for 2 weeks, and clinical score, weight loss,
and death (or moribund condition mandating euthanasia)
were recorded on a daily basis15. Mice receiving DENV2-
exposed CD8+ T cells exhibited less disease based on clinical
scores (Fig. 5b), weight loss (Fig. 5c), and mortality (Fig. 5d)
relative to mice receiving naive CD8+ T cells (Fig. 5a–d). Indeed,
90% of mice with DENV2-exposed CD8+ T cells survived
compared to only 10% of mice that received naive CD8+ T cells.
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These results demonstrate that DENV-reactive CD8+ T cells can
confer cross-protection against lethal ZIKV infection in mice.
Discussion
The close relationships between DENV and ZIKV at the amino
acid sequence and serologic levels indicate possibilities for cross-
protection or immune enhancement during sequential DENV
and ZIKV infections. A study focusing on cross-reactive T cell
responses in Ifnar1−/− HLA-transgenic mice has shown that prior
DENV immunity alters immunodominance patterns of CD8+ T
cell responses to subsequent ZIKV infection38, while another has
demonstrated that passive transfer of DENV-immune plasma
into naive Stat2−/− mice can enhance ZIKV infection and disease
severity12. Based on these ﬁndings, the following question needs
to be answered urgently: What is the role of prior DENV
immunity during sequential ZIKV infection of the same host?
Epidemiologic studies in humans will take years to perform, and
the precise contributions of cellular vs. humoral immunity cannot
be easily dissected in humans. The goals of our study were to
determine the impact of DENV immunity on the outcome of
subsequent ZIKV infection, and to identify the immune com-
ponents responsible for any such inﬂuence. We observed that
DENV immunity signiﬁcantly reduced infectious ZIKV burden in
sera and tissues. Humoral vs. CD8+ T cell contributions were
isolated and quantiﬁed via CD8+ T cell depletion of DENV-
immune mice, and adoptive transfer of DENV-immune serum or
CD8+ T cells to naive mice. DENV-immune mice contained high
levels of DENV-binding and DENV-neutralizing Abs but low
levels of ZIKV-binding and ZIKV-neutralizing Abs, as measured
by ELISA and in vitro neutralization assays, and passive transfer
experiments revealed no role for DENV-immune sera in pro-
tection against ZIKV in mice. In contrast, T cell depletion and
adoptive transfer studies demonstrated that ZIKV protection was
mediated principally by DENV-exposed CD8+ T cells. This result
is consistent with prior murine studies demonstrating that
DENV-speciﬁc CD8+ T cells can confer protection in the context
of heterotpyic DENV serotype and ADE infections43,44. A short
period of cross-protection against heterotypic infection by other
DENV serotypes has been well documented in humans47–50. This
cross-protection in humans has been assumed to rely on high
titers of cross-reactive Abs reactive for all DENV serotypes
despite the lack of experimental evidence51–53. More recent stu-
dies examining the anti-DENV T cell response in humans sup-
port a protective role for T cells against DENV infection in
humans36,37,54, in agreement with published studies in
mice40–44,55,56. Based on our results, we speculate that the anti-
DENV CD8+ T cell response in humans will mediate at least
transient cross-protection against subsequent ZIKV infection57.
At present, it remains unknown whether human DENV
immunity is protective or pathogenic against ZIKV infection.
Documentation of cross-reactivity between DENV and ZIKV in
humoral8–11 and cellular immune compartments38 is growing.
Although many studies have explored the Ab cross-reactivity
between DENV and ZIKV, the exact role of prior DENV humoral
immunity during subsequent ZIKV infection also is uncertain58.
In vitro, cross-reactive murine DENV Abs can enhance ZIKV
infection22,59 and human DENV Abs can neutralize5,9–11,60,61 or
enhance9,10,12,22,62,63 ZIKV infection depending on their epitope
speciﬁcity and avidity. In vivo, human DENV Abs can protect
mice against ZIKV infection11,61 or mediate ADE12. These results
are not surprising, as the anti-DENV Ab response can exhibit
protection, enhancement, or no effect depending on epitope
speciﬁcity, virion binding activity, concentration, and avidity,
albeit the precise characteristics of the anti-ﬂavivirus Ab response
that produces these different outcomes are not fully understood.
Neutralization vs. enhancement vs. no effect outcomes are
functions of the stoichiometry of Ab binding to the viral particles
and infection of cells expressing Fc-gamma receptors64,65. Results
in our study demonstrate that DENV-immune Abs derived from
mouse serum can neutralize ZIKV in vitro, but are not sufﬁcient
to protect against or enhance infection at the amounts we tested
in vivo. The lack of ADE that we observed with DENV-immune
mouse sera contrasts with enhanced ZIKV pathogenesis described
in Stat2−/− mice that were passively transferred DENV-immune
human plasma;12 this disparity may be due to differences in the
plasma-derived Ab preparations and/or mouse models (WT and
Ifnar1−/− vs. Stat2−/−). Similar to our results, two recent rhesus
macaque studies showed that DENV-immune serum could neu-
tralize ZIKV infection in vitro and did not promote ADE against
ZIKV in vivo66,67. One of these studies with rhesus macaques
showed a reduction in the duration of ZIKV viremia in DENV-
immune animals relative to naive controls, suggesting cross-
protection67. However, in the second rhesus macaque study, prior
DENV immunity failed to confer protection against subsequent
ZIKV infection66. This lack of robust cross-protection in maca-
que may have several explanations: (a) DENV does not establish
signiﬁcant levels of infection in non-human primates68 and thus
may not induce a robust anti-DENV immune response; accord-
ingly, the anti-DENV T cell response may not be protective, and
the cross-reactive Ab response may be too weak to protect against
or enhance ZIKV infection; (b) animals in both studies were
challenged with ZIKV at 1–2 years after DENV infection. Thus, a
transient period of cross-immunity may have waned by the time
of ZIKV challenge. Studies using mice that have been exposed to
DENV for greater lengths of time than 1 month (such as 3, 6, and
12 months) may help answer questions related to the window of
cross-protection.
Our results agree with emerging literature implicating a com-
plex interplay between humoral and cellular immunity in
ﬂavivirus-experienced individuals. There is evidence that some
individuals mount weaker CD8+ T cell responses than others;
these weaker T cell responses, in combination with suboptimal
Ab responses, may lead to severe disease manifestations, whereas
an efﬁcient T cell or Ab response alone may be sufﬁcient for
protection. Recent studies have revealed that the magnitude and
breadth of DENV-speciﬁc CD8+ T cell and CD4+ T cell responses
correlate with speciﬁc HLA alleles36,37,54,69,70. Investigations in
HLA transgenic mice also showed that CD8+ T cell responses to
ZIKV are stronger in HLA-B*0702 mice than HLA-A*0101
mice38. However, the net impact of HLA and T cell responses on
ZIKV infection and pathogenesis can only be determined through
Fig. 2 The effect of DENV2-immune sera on ZIKV infection in vitro and in Ifnar1−/− mice. Ifnar1−/− mice were immunized intraperitoneally with DENV2
(2 × 102 FFU) for 28 days. Naive Ifnar1−/− mouse sera (n= 10) and DENV2-immune Ifnar1−/− mouse sera (n= 10) were examined for their ability to
neutralize DENV2 or ZIKV using U937 DC-SIGN cells and a ﬂow cytometry-based neutralization assay (a). Data were pooled from two independent
experiments with n= 5 mouse sera per group and expressed as mean± SEM. Different volumes of naive and DENV2-immune Ifnar1−/− mouse sera were
passively transferred (retro-orbital route) to naive recipient Ifnar1−/− mice (b, c). Three days post retro-orbital challenge with 1 × 104 FFU of ZIKV
FSS13025, viral burdens in sera and indicated organs were measured using FFA. In b, data are pooled from two independent experiments (n= 3–4 mice per
group per experiment), while results in c represent one experiment. Data are expressed as mean± SEM. **p< 0.01. b A Kruskal–Wallis one-way ANOVA.
c Two-tailed Mann–Whitney test. Supplementary Tables 1 and 2 provide exact values of n and p
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a combination of clinical studies, epidemiologic studies, and
vaccine and antiviral trials.
If some individuals have genetic or acquired predispositions
to weaker CD8+ T cell responses to viruses such as DENV and
ZIKV, these people may not be protected in the scenarios
of sequential ﬂavivirus infection or vaccination followed by
heterologous infection. An inadequate CD8+ T cell response
in the presence of enhancing levels of Abs may account for some
of the worsened dengue outcomes seen in individuals
vaccinated for Japanese encephalitis virus25 or a heterologous
DENV serotype26. Based on ﬁndings of the present study and
two recent publications12,38, an inefﬁcient CD8+ T cell response,
in combination with ADE, might have contributed to severe
ZIKV disease manifestations in individuals with prior DENV
exposure during the 2015–2016 ZIKV epidemic in Latin America.
As the geographic ranges of ﬂaviviruses continue to expand
and merge, and human hosts travel globally, ﬂavivirus
vaccines that are engineered to induce both robust CD8+ T cell
and Ab responses may be critical to achieve maximal efﬁcacy
and safety.
Methods
Mice and ethics statement. Ifnar1−/− (C57BL/6 background) and WT C57BL/6
mice were originally obtained from Dr. W. Yokoyama (Washington University in
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Fig. 3 Reduced ZIKV burden in Ifnar1−/− mice adoptively transferred with DENV2-exposed CD8+ T cells. Naive (1 × 107) and DENV2-exposed CD8+ T cells
(1 × 107) from Ifnar1−/− mice were adoptively transferred to naive recipient Ifnar1−/− mice. Three days post ZIKV challenge (1 × 104 FFU of ZIKV FSS13025,
retro-orbital route), cross-reactive peptide-speciﬁc CD8+ T cell responses (a) and ZIKV levels in sera and indicated organs (b) were detected by ICS
assay and FFA, respectively. Data are pooled from two independent experiments (n= 3–4 mice per group per experiment) and expressed as mean± SEM.
*p< 0.05, **p< 0.01, ***p< 0.001,****p< 0.0001. a A Kruskal–Wallis one-way ANOVA. b Two-tailed Mann–Whitney test. Supplementary Tables 1 and 2
provide exact values of n and p
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St. Louis) via Dr. Carl Ware (La Jolla Institute for Allergy and Immunology) and
the Jackson Laboratory (USA), respectively. All mice were maintained and bred at
the La Jolla Institute for Allergy & Immunology under standard pathogen free
conditions. All mouse experiments were approved by the Institutional Animal
Care and Use Committee under protocol #AP028-SS1-0615. Sample sizes were
estimated based on previous similar studies. Animal experiments were not
randomized or blinded.
Peptide synthesis. H-2b-restricted CD8+ T cell epitopes in ZIKV were identiﬁed
previously39 (Supplementary Table 3). Five DENV2 variants of the ZIKV epitopes
that stimulated cross-reactive DENV2-exposed CD8+ T cells also were selected.
Peptides were synthesized by Synthetic Biomolecules with a purity >95%
conﬁrmed by mass spectrometry. All peptides were dissolved in DMSO to
40 mg/ml and stored at −80 °C.
Viruses, cells, and reagents. ZIKV Asian lineage strain FSS13025 (Cambodia,
2010) was obtained from the World Reference Center for Emerging Viruses and
Arboviruses (WRCEVA) and propagated in C6/36 Aedes albopictus cells (ATCC®
CRL-1660™). The mouse-adapted DENV2 strain S221 is derived from DENV2
D2S1040. Baby Hamster Kidney (BHK)-21 cells and U937 DC-SIGN cells were
purchased from the American Type Culture Collection (ATCC). ZIKV and
DENV2 titers were analyzed on BHK-21 cells using focus-forming assay (FFA) and
expressed as FFU/ml. PE-conjugated mouse anti-human CD209 monoclonal
antibody (mAb) (clone DCN46) and Brefeldin A (BFA) were purchased from BD
Biosciences. DENV-speciﬁc mAb 2H2 (clone D3-2H2-9-21) and pan Flavivirus-
speciﬁc mAb 4G2 hybridoma (clone D1-4G2-4-15) were purchased from the
ATCC, and puriﬁed mAbs were obtained from BioXCell. Ab used for mouse CD8+
T cell depletion (rat anti-mouse CD8 mAb, clone 2.43) and isotype control Ab (rat
IgG2, clone LTF-2) were purchased from BioXCell. IFNAR1-blocking mAb MAR1-
5A3 also was purchased from BioXCell. Mouse CD8+ T cell magnetic positive
selection microbeads were purchased from Miltenyi Biotec. Rat anti-mouse CD3
PerCpCy 5.5 (clone 145-2C11) and anti-IFNγ FITC (clone XMG 1.2) were
purchased from Tonbo Biosciences. Rat anti-mouse CD8 PE-Cy7 (clone 53–67),
anti-CD107a PE (clone 1D4B), anti-TNF APC (clone MP6-XT22), 3,3′,5,5′-Tet-
ramethylbenzidine (TMB), and Phorbol 12-myristate 13-acetate (PMA)/Ionomycin
were purchased from eBioscience. Horseradish peroxidase (HPR)-conjugated goat
anti-mouse IgG and carboxymethyl cellulose (CMC) were purchased from Sigma.
True Blue substrate was purchased from KPL. The ZIKV envelope (E) protein was
purchased from the Native Antigen Company.
Mouse infections. Five-to-six-week-old Ifnar1−/− male and female mice were
infected with 2 × 104 FFU of DENV2 or 1 × 102 FFU of ZIKV via retro-orbital
route. After 7 days, mice were sacriﬁced, and splenocytes were used for an ICS
assay. In addition, 5-to-6-week-old Ifnar1−/− mice were inoculated with 2 × 102
FFU DENV2 via intra-peritoneal route for 28 days, and these DENV2-immune
mice were used for CD8+ T cell depletion, CD8+ T cell isolation, or serum
collection. Five-to-six-week-old WT mice were administered 2 mg IFNAR1-
blocking mAb MAR1-5A3 intraperitoneally 1 day before inoculation with 1 × 104
FFU of DENV2 via retro-orbital route. After 28 days, these DENV2-immune WT
mice were used for CD8+ T cell isolation or serum collection.
ZIKV challenge of CD8+ T cell-depleted DENV2-immune mice. Age-matched
naive and DENV2-immune Ifnar1−/− mice were injected intraperitoneally with
either rat anti-mouse CD8 Ab (250 μg/mouse) or isotype control Ab (250 μg/
mouse, rat IgG2) at day-3 and day-1 before ZIKV challenge. Ifnar1−/− mice were
challenged retro-orbitally with 1 × 104 FFU of ZIKV FSS13025. Three days after
ZIKV challenge, mice were sacriﬁced, and serum and spleen were harvested.
Spleens were used for ICS assay. After cardiac perfusion with PBS, liver, testis,
brain, and eye were harvested. ZIKV titers in sera and other tissues of Ifnar1−/−
mice were quantiﬁed using a FFA.
DENV2-binding and ZIKV-binding IgG ELISA. Sera were harvested from naive or
DENV2-immune Ifnar1−/− mice on day 28 after infection. Ninety six-well ELISA
plates were incubated with either UV-inactivated DENV2 (2 × 104 FFU/well) or
ZIKV E protein (1 μg/ml) in 50 μl coating buffer 0.1 M NaHCO3 overnight at 4 °C.
The plates were then washed to remove unbound virus or ZIKV protein and
blocked for 1 h at room temperature (RT). Sera were diluted to 1:30, 1:90, 1:270,
1:810, 1:2430, 1:7290, 1:21870, and 1:65610, and added to individual wells
(100 μl/well). After 1.5 h of incubation at RT, plates were washed and bound Ab
was detected using HRP-conjugated goat anti-mouse IgG (at a dilution of 1:500).
The plates were developed with 3,3′,5,5′-TMB and the absorbance was read at
450 nm. EPTs were deﬁned as reciprocal serum dilutions that corresponded to two
times the average OD values obtained with naive serum.
Serum neutralization assay. Flow cytometry-based assay was used to evaluate
neutralization of DENV2 and ZIKV in vitro by immune sera. Both naive and
DENV2-immune mouse sera were inactivated for 30 min at 56 °C. In brief, sera
were diluted in 96-well round bottom plates to 1:10, 1:30, 1:90, 1:270, 1:810, 1:2430,
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Fig. 4 Reduced ZIKV burden in WT mice adoptively transferred with DENV2-exposed CD8+ T cells. Naive or DENV2-exposed CD8+ T cells (1 × 107) from
WT mice were adoptively transferred to naive recipient WT mice that were intraperitoneally injected with 2 mg of the IFNAR1-blocking mAb MAR1-5A3
1 day before ZIKV challenge. Three days post ZIKV challenge (1 × 106 FFU of FSS13025, retro-orbital route), cross-reactive peptide-speciﬁc CD8+ T cell
responses (a) and ZIKV levels in serum and liver (b) were detected by ICS assay and FFA, respectively. Data are pooled from two independent experiments
(n= 4–6 mice per group per experiment) and expressed as mean± SEM. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001. a A Kruskal–Wallis one-way
ANOVA. b Two-tailed Mann–Whitney test. Supplementary Tables 1 and 2 give exact values of n and p
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and 1:7290. DENV2 S221 or ZIKV FSS13025 was added to diluted sera (2 × 104
FFU of DENV2/ZIKV per well). After 1 h incubation at 37 °C, U937 DC-SIGN cells
were seeded in each well (1 × 105 cells/well). The plates were incubated for 2 h at
37 °C (rocking every 15 min). Cells without serum were used as positive control.
After incubation, the plates were centrifuged for 5 min at 300 × g, and supernatants
were aspirated. Fresh medium was added to plates and incubated for 16 h at 37 °C.
After ﬁxation and permeabilization using Cytoﬁx/Cytoperm solution (BD
Biosciences), cells were stained with anti-CD209 PE (a dilution of 1:100) and a
mixture of 4G2 FITC/2H2 FITC (1 μg/ml). Cells were analyzed on an LSRII ﬂow
cytometer (BD Biosciences, CA, USA) and the percentages of infected cells were
determined using FlowJo software X 10.0.7. Percent inhibition for diluted serum
was calculated using Eq. (1):
Percent inhibition ¼ Positive control testð Þ
Positive control
ð1Þ
ZIKV challenge of mice transferred with DENV-immune serum. Naive and
DENV2-immune mice were sacriﬁced and sera were collected. Pooled naive and
DENV2-immune Ifnar1−/− mice sera were transferred passively (via retro-orbital
route) to 5-week-old naive Ifnar1−/− mice (600, 300 μl naive sera/mouse; 600, 300,
100, 33 μl DENV2-immune sera/mouse). Pooled naive and DENV2-immune sera
from WT mice were retro-orbitally transferred to 2-week-old or 4-week-old naive
WT mice (200, 75 μl naive sera/mouse; 200, 75, 25, 8.3 μl DENV2-immune sera/
mouse) that had received 1 or 2 mg IFNAR1-blocking mAb MAR1-5A3 (intra-
peritoneal route) 1 h prior to serum transfer. One day after serum transfer, mice
were infected retro-orbitally with 1 × 104 FFU, 5 × 104 FFU, or 1 × 106 FFU of
ZIKV FSS13025. Three days after challenge, mouse serum, spleen, liver, testis,
brain, and eye were harvested.
ZIKV challenge of mice transferred with DENV-exposed T cells. Naive and
DENV2-immune Ifnar1−/− or WT mice were sacriﬁced and CD8+ T cells were
isolated from splenocytes using magnetic positive selection Ab-coated microbeads
(MiltenyiBiotec). Naive and DENV2-exposed CD8+ T cells were adoptively
transferred to naive Ifnar1−/− or WT mice (1 × 107 naive CD8+ T cells, 1 × 107
DENV2-exposed CD8+ T cells/mouse). One day later, Ifnar1−/− mice were infected
retro-orbitally with 1 × 104 FFU of ZIKVFSS13025, whereas WT mice with IFNAR
blockade (via intraperitoneal injection of 2 mg IFNAR1-blocking Ab MAR1-5A3
1 day before ZIKV challenge) were infected retro-orbitally with 1 × 106 FFU of
ZIKV FSS13025. Three days after ZIKV challenge, mouse serum, spleen, liver,
testis, brain, and eye were harvested.
DENV-exposed CD8+ T cell adoptive transfer and survival study. Naive and
DENV2-immune Ifnar1−/− CD8+ T cells were injected retro-orbitally into naive
Ifnar1−/− recipients (1 × 107 naive CD8+ T cells/mouse, 1 × 107 DENV2-exposed
CD8+ T cells/mouse). One day later, mice were inoculated retro-orbitally with
1 × 103 FFU of ZIKV FSS13025. Weight loss and death (or moribund condition
mandating euthanasia) were recorded on each day.
Intracellular cytokine staining. Splenocytes were plated (1 × 106 per well, in 200
μl) in 96-well round-bottom plates and stimulated with 1 μg of individual peptide
for 6 h in the presence of BFA and anti-CD107a PE (for the last 5 h, a dilution of
1:100). Cells stimulated with PMA/Ionomycin (P/I) (a dilution of 1:500) and cells
without stimulation were used as positive and negative controls, respectively.
After incubation, cells were stained with Abs against CD3 (a dilution of 1:100) and
CD8 antigens (a dilution of 1:100). After ﬁxation and permeabilization using
Cytoﬁx/Cytoperm buffer, cells were incubated with anti-IFNγ (a dilution of 1:200)
and anti-TNF mAb (a dilution of 1:200). Samples were processed on a LSRII ﬂow
cytometer and analyzed using FlowJo software X 10.0.7.
Viral burden analysis. FFA was performed with BHK-21 cells as described39.
Mouse organs (in 1 ml MEM medium) were homogenized for 3 min using
Tissuelyser II (Qiagen Inc.) and then centrifuged for 5 min at 400 × g. 100 μl
supernatant or serum or DENV2/ZIKV viral suspension was diluted serially and
added to cells in duplicate and incubated for 1 h. After aspirating supernatant, wells
were overlaid with 1% CMC medium. Two and half days after infection, cells were
ﬁxed with 4% formalin (Fisher Chemicals), permeabilized with 1% Triton X,
and blocked with 10% FBS/PBS solution. Plates were incubated with the pan
Flavivirus-speciﬁc mAb 4G2 (1 μg/ml), and then HPR-conjugated goat anti-mouse
IgG (a dilution of 1:1000). Foci were developed using True Blue substrate and
counted manually.
Statistical analysis. All data were analyzed using Prism 6 software (GraphPad
Software, Inc.) and expressed as mean± SEM. Grubbs’ test was performed to detect
outliers. A Kruskal–Wallis one-way ANOVA was used for multiple comparisons.
Comparison between two groups was performed using Mann–Whitney test.
Weight loss was analyzed by two-way ANOVA. Survival data were analyzed using
the log rank test. P< 0.05 was deemed a statistically signiﬁcant difference.
Data availability. The data that support the ﬁndings of this study are available
from the corresponding author on request.
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Fig. 5 Decreased ZIKV-induced morbidity and mortality in Ifnar1−/− mice adoptively transferred with DENV2-exposed CD8+ T cells. Naive or DENV2-
exposed CD8+ T cells (1 × 107) from Ifnar1−/− mice were adoptively transferred via the retro-orbital route to recipient Ifnar1−/− mice. One day later, mice
were retro-orbitally challenged with 1 × 103 FFU of ZIKV FSS13025. Clinical score (a, b), weight loss (c), and survival rates (d) were recorded daily. Mice
having >20% weight loss and/or exhibiting paralysis of two hind limbs were euthanized according to Animal Protocols. This experiment was performed
twice with n= 5 mice per group per experiment. Data represent pooled data from 10 mice per group and expressed as mean± SEM. *p< 0.05, ***p<
0.001, ****p< 0.0001. c Two-way ANOVA. d Log rank test. Supplementary Tables 1 and 2 give exact values of n and p
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